...belongs to a group of drugs called antiseizure drugs. Fintepla is a brand-name medication. A generic version of the drug isn’t currently available. Fintepla has a boxed warning. A boxed...
...talk with your doctor or pharmacist. The table below lists drugs that may interact with Pradaxa. Keep in mind that this table does not include all drugs that may interact...
...other drugs? Before you start taking Fosamax, tell your doctor and pharmacist about any prescription, over-the-counter, or other drugs you take. Sharing this information with them may help prevent possible...
...is treated with antiretroviral drugs (ARVs), which are drugs specially designed to treat retroviruses. People with HIV have been prescribed a combination of antiretroviral drugs, which together are known as...
...an oral solution, oral capsule, and oral tablet called Imodium A-D. Unless otherwise noted, this article uses “Imodium” to describe all forms of the drug. Keep reading to learn about...
...muscle relaxants that contain the same active ingredient: cyclobenzaprine hydrochloride. And both drugs are recommended for short-term use (3 weeks or less). But the dosages of these drugs differ. Amrix...
...people with antiviral drugs to limit complications, potentially requiring hospitalization to administer drugs intravenously. Antiviral drugs are the same as those given to immunocompetent people. Treatment of postherpetic neuralgia Early...
...the drugs that are introduced intravenously are called specialty pharmaceuticals or specialty drugs. Intravenous therapy delivers two types of fluids, crystalloids and colloids. Crystalloids are liquid forms of minerals, salts,...
...require treatment, drug therapy is one of the options and is recommended for patients with symptomatic tachycardias, atrial fibrillation and premature beats. A variety of antiarrhythmic drugs can be used...
...so steroid tablets will generally only be used if there is a risk of permanent damage to the eyes. It is important to continue using the tablets as prescribed even...
